Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Cefpirome Treatment Results in Limited Selection of Stable Derepressed Enterobacter cloacae Mutants in the Intestinal Flora of Rats Treated for an Experimental Klebsiella pneumoniae Pulmonary Infection.

Gautam V, Mouton JW, Ten Kate MT, Bakker-Woudenberg IAJM, van Burgh S, Strepis N, Klaassen CHW, Goessens W.

Microb Drug Resist. 2019 Oct 29. doi: 10.1089/mdr.2018.0473. [Epub ahead of print]

PMID:
31657651
2.

Antimicrobial activity of two novel antimicrobial peptides AA139 and SET-M33 against clinically and genotypically diverse Klebsiella pneumoniae isolates with differing antibiotic resistance profiles.

van der Weide H, Vermeulen-de Jongh DMC, van der Meijden A, Boers SA, Kreft D, Ten Kate MT, Falciani C, Pini A, Strandh M, Bakker-Woudenberg IAJM, Hays JP, Goessens WHF.

Int J Antimicrob Agents. 2019 Aug;54(2):159-166. doi: 10.1016/j.ijantimicag.2019.05.019. Epub 2019 Jun 5.

PMID:
31173867
3.

Antibiotic-nanomedicines: facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections.

Ritsema JA, der Weide HV, Te Welscher YM, Goessens WH, van Nostrum CF, Storm G, Bakker-Woudenberg IA, Hays JP.

Future Microbiol. 2018 Nov;13:1683-1692. doi: 10.2217/fmb-2018-0194. Epub 2018 Nov 30.

PMID:
30499686
4.

Chitinase Induction Prior to Caspofungin Treatment of Experimental Invasive Aspergillosis in Neutropenic Rats Does Not Enhance Survival.

Refos JM, Vonk AG, Ten Kate MT, Verbrugh HA, Bakker-Woudenberg IAJM, van de Sande WWJ.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e00960-17. doi: 10.1128/AAC.00960-17. Print 2018 Jan.

5.

Differential epitope recognition in the immunodominant staphylococcal antigen A of Staphylococcus aureus by mouse versus human IgG antibodies.

Koedijk DGAM, Pastrana FR, Hoekstra H, Berg SVD, Back JW, Kerstholt C, Prins RC, Bakker-Woudenberg IAJM, van Dijl JM, Buist G.

Sci Rep. 2017 Aug 15;7(1):8141. doi: 10.1038/s41598-017-08182-9.

6.

Addition of 17-(allylamino)-17-demethoxygeldanamycin to a suboptimal caspofungin treatment regimen in neutropenic rats with invasive pulmonary aspergillosis delays the time to death but does not enhance the overall therapeutic efficacy.

Refos JM, Vonk AG, Ten Kate MT, Eadie K, Verbrugh HA, Bakker-Woudenberg IAJM, van de Sande WWJ.

PLoS One. 2017 Jul 24;12(7):e0180961. doi: 10.1371/journal.pone.0180961. eCollection 2017.

7.

The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.

Bax HI, Bakker-Woudenberg IAJM, de Vogel CP, van der Meijden A, Verbon A, de Steenwinkel JEM.

Tuberculosis (Edinb). 2017 Jul;105:80-85. doi: 10.1016/j.tube.2017.04.010. Epub 2017 Apr 27.

PMID:
28610791
8.

Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model.

de Knegt GJ, Dickinson L, Pertinez H, Evangelopoulos D, McHugh TD, Bakker-Woudenberg IAJM, Davies GR, de Steenwinkel JEM.

Tuberculosis (Edinb). 2017 Jul;105:113-118. doi: 10.1016/j.tube.2017.05.002. Epub 2017 May 8.

9.

Investigations into the killing activity of an antimicrobial peptide active against extensively antibiotic-resistant K. pneumon iae and P. aeruginosa.

van der Weide H, Brunetti J, Pini A, Bracci L, Ambrosini C, Lupetti P, Paccagnini E, Gentile M, Bernini A, Niccolai N, Jongh DV, Bakker-Woudenberg IAJM, Goessens WHF, Hays JP, Falciani C.

Biochim Biophys Acta Biomembr. 2017 Oct;1859(10):1796-1804. doi: 10.1016/j.bbamem.2017.06.001. Epub 2017 Jun 3.

10.

Immunotherapy Added to Antibiotic Treatment Reduces Relapse of Disease in a Mouse Model of Tuberculosis.

Mourik BC, Leenen PJ, de Knegt GJ, Huizinga R, van der Eerden BC, Wang J, Krois CR, Napoli JL, Bakker-Woudenberg IA, de Steenwinkel JE.

Am J Respir Cell Mol Biol. 2017 Feb;56(2):233-241. doi: 10.1165/rcmb.2016-0185OC.

PMID:
27654457
11.

Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro.

Bax HI, Bakker-Woudenberg IA, Ten Kate MT, Verbon A, de Steenwinkel JE.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2577-9. doi: 10.1128/AAC.02864-15. Print 2016 Apr.

12.

Colistin as a potentiator of anti-TB drug activity against Mycobacterium tuberculosis.

Bax HI, de Steenwinkel JE, Ten Kate MT, van der Meijden A, Verbon A, Bakker-Woudenberg IA.

J Antimicrob Chemother. 2015 Oct;70(10):2828-37. doi: 10.1093/jac/dkv194. Epub 2015 Jul 16.

PMID:
26183185
13.

Mild Staphylococcus aureus Skin Infection Improves the Course of Subsequent Endogenous S. aureus Bacteremia in Mice.

van den Berg S, de Vogel CP, van Belkum A, Bakker-Woudenberg IA.

PLoS One. 2015 Jun 10;10(6):e0129150. doi: 10.1371/journal.pone.0129150. eCollection 2015.

14.

SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.

de Knegt GJ, Bakker-Woudenberg IA, van Soolingen D, Aarnoutse R, Boeree MJ, de Steenwinkel JE.

Int J Antimicrob Agents. 2015 Jul;46(1):66-72. doi: 10.1016/j.ijantimicag.2015.02.025. Epub 2015 Apr 17.

PMID:
25951996
15.

Active immunization with an octa-valent Staphylococcus aureus antigen mixture in models of S. aureus bacteremia and skin infection in mice.

van den Berg S, Koedijk DG, Back JW, Neef J, Dreisbach A, van Dijl JM, Bakker-Woudenberg IA, Buist G.

PLoS One. 2015 Feb 24;10(2):e0116847. doi: 10.1371/journal.pone.0116847. eCollection 2015.

16.

Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.

de Knegt GJ, ten Kate MT, van Soolingen D, Aarnoutse R, Boeree MJ, Bakker-Woudenberg IA, de Steenwinkel JE.

Tuberculosis (Edinb). 2014 Dec;94(6):701-7.

PMID:
25621361
17.

A human monoclonal antibody targeting the conserved staphylococcal antigen IsaA protects mice against Staphylococcus aureus bacteremia.

van den Berg S, Bonarius HP, van Kessel KP, Elsinga GS, Kooi N, Westra H, Bosma T, van der Kooi-Pol MM, Koedijk DG, Groen H, van Dijl JM, Buist G, Bakker-Woudenberg IA.

Int J Med Microbiol. 2015 Jan;305(1):55-64. doi: 10.1016/j.ijmm.2014.11.002. Epub 2014 Nov 11.

PMID:
25466204
18.

Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.

de Knegt GJ, Ten Kate MT, van Soolingen D, Aarnoutse R, Boeree MJ, Bakker-Woudenberg IA, de Steenwinkel JE.

Tuberculosis (Edinb). 2014 Oct 13. pii: S1472-9792(14)20507-5. doi: 10.1016/j.tube.2014.09.002. [Epub ahead of print]

PMID:
25423883
19.

Evidence supporting a role for mammalian chitinases in efficacy of caspofungin against experimental aspergillosis in immunocompromised rats.

Verwer PE, ten Kate MT, Falcone FH, Morroll S, Verbrugh HA, Bakker-Woudenberg IA, van de Sande WW.

PLoS One. 2013 Oct 14;8(10):e75848. doi: 10.1371/journal.pone.0075848. eCollection 2013.

20.

Discrimination of Aspergillus lentulus from Aspergillus fumigatus by Raman spectroscopy and MALDI-TOF MS.

Verwer PE, van Leeuwen WB, Girard V, Monnin V, van Belkum A, Staab JF, Verbrugh HA, Bakker-Woudenberg IA, van de Sande WW.

Eur J Clin Microbiol Infect Dis. 2014 Feb;33(2):245-51. doi: 10.1007/s10096-013-1951-4. Epub 2013 Sep 13.

PMID:
24030717
21.

Mycobacterium tuberculosis Beijing type mutation frequency--author's response.

de Steenwinkel JE, Soolingen Dv, Bakker-Woudenberg IA.

Emerg Infect Dis. 2013 Mar;19(3):522-3. No abstract available.

22.

Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model.

de Steenwinkel JE, Aarnoutse RE, de Knegt GJ, ten Kate MT, Teulen M, Verbrugh HA, Boeree MJ, van Soolingen D, Bakker-Woudenberg IA.

Am J Respir Crit Care Med. 2013 May 15;187(10):1127-34. doi: 10.1164/rccm.201207-1210OC.

PMID:
23525933
23.

Distinctive cytokines as biomarkers predicting fatal outcome of severe Staphylococcus aureus bacteremia in mice.

van den Berg S, Laman JD, Boon L, ten Kate MT, de Knegt GJ, Verdijk RM, Verbrugh HA, Nouwen JL, Bakker-Woudenberg IA.

PLoS One. 2013;8(3):e59107. doi: 10.1371/journal.pone.0059107. Epub 2013 Mar 8.

24.

Relapse of tuberculosis versus primary tuberculosis; course, pathogenesis and therapy in mice.

de Steenwinkel JE, de Knegt GJ, ten Kate MT, Verbrugh HA, Hernandez-Pando R, Leenen PJ, Bakker-Woudenberg IA.

Tuberculosis (Edinb). 2013 Mar;93(2):213-21. doi: 10.1016/j.tube.2012.11.006. Epub 2012 Dec 23.

PMID:
23266260
25.

Rifampicin-induced transcriptome response in rifampicin-resistant Mycobacterium tuberculosis.

de Knegt GJ, Bruning O, ten Kate MT, de Jong M, van Belkum A, Endtz HP, Breit TM, Bakker-Woudenberg IA, de Steenwinkel JE.

Tuberculosis (Edinb). 2013 Jan;93(1):96-101. doi: 10.1016/j.tube.2012.10.013. Epub 2012 Nov 22.

PMID:
23182912
26.

The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats.

Goessens WH, Mouton JW, Ten Kate MT, Sörgel F, Kinzig M, Bakker-Woudenberg IA.

Antimicrob Agents Chemother. 2013 Jan;57(1):643-6. doi: 10.1128/AAC.01154-12. Epub 2012 Nov 5.

27.

Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis.

de Steenwinkel JE, ten Kate MT, de Knegt GJ, Verbrugh HA, Aarnoutse RE, Boeree MJ, den Bakker MA, van Soolingen D, Bakker-Woudenberg IA.

Antimicrob Agents Chemother. 2012 Sep;56(9):4937-44. doi: 10.1128/AAC.00124-12. Epub 2012 Jul 16.

28.

Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB.

de Steenwinkel JE, ten Kate MT, de Knegt GJ, Kremer K, Aarnoutse RE, Boeree MJ, Verbrugh HA, van Soolingen D, Bakker-Woudenberg IA.

Emerg Infect Dis. 2012 Apr;18(4):660-3. doi: 10.3201/eid1804.110912.

29.

Reshuffling of Aspergillus fumigatus cell wall components chitin and β-glucan under the influence of caspofungin or nikkomycin Z alone or in combination.

Verwer PE, van Duijn ML, Tavakol M, Bakker-Woudenberg IA, van de Sande WW.

Antimicrob Agents Chemother. 2012 Mar;56(3):1595-8. doi: 10.1128/AAC.05323-11. Epub 2011 Dec 27.

30.

Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.

de Steenwinkel JE, ten Kate MT, de Knegt GJ, Verbrugh HA, van Belkum A, Hernandez-Pando R, Bakker-Woudenberg IA.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1478-84, i. doi: 10.5588/ijtld.11.0012.

PMID:
22008760
31.

Dynamics of interferon-gamma release assay and cytokine profiles in blood and respiratory tract specimens from mice with tuberculosis and the effect of therapy.

de Steenwinkel JE, de Knegt GJ, ten Kate MT, Verbrugh HA, Ottenhoff TH, Bakker-Woudenberg IA.

Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1195-201. doi: 10.1007/s10096-011-1428-2. Epub 2011 Oct 9.

32.

Cryptococcus and Trichosporon spp. are susceptible in vitro to branched histidine- and lysine-rich peptides (BHKPs).

Verwer PE, Woodle MC, Boekhout T, Hagen F, Bakker-Woudenberg IA, van de Sande WW.

J Antimicrob Chemother. 2011 Jul;66(7):1649-52. doi: 10.1093/jac/dkr175. Epub 2011 May 4. No abstract available.

PMID:
21543360
33.

A multiplex assay for the quantification of antibody responses in Staphylococcus aureus infections in mice.

van den Berg S, Bowden MG, Bosma T, Buist G, van Dijl JM, van Wamel WJ, de Vogel CP, van Belkum A, Bakker-Woudenberg IA.

J Immunol Methods. 2011 Feb 28;365(1-2):142-8. doi: 10.1016/j.jim.2010.12.013. Epub 2010 Dec 23.

34.

Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.

de Steenwinkel JE, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, van Soolingen D, Bakker-Woudenberg IA.

J Antimicrob Chemother. 2010 Dec;65(12):2582-9. doi: 10.1093/jac/dkq374. Epub 2010 Oct 14.

PMID:
20947621
35.

Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.

van de Sande WW, Fahal AH, Bakker-Woudenberg IA, van Belkum A.

Antimicrob Agents Chemother. 2010 Jun;54(6):2738-40. doi: 10.1128/AAC.01546-09. Epub 2010 Mar 29.

36.

The effects of antifungal agents to conidial and hyphal forms of Aspergillus fumigatus.

van de Sande WW, Tavakol M, van Vianen W, Bakker-Woudenberg IA.

Med Mycol. 2010 Feb;48(1):48-55. doi: 10.3109/13693780802713497.

PMID:
20055743
37.

Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice.

De Steenwinkel JE, De Knegt GJ, Ten Kate MT, Van Belkum A, Verbrugh HA, Hernandez-Pando R, Van Soolingen D, Bakker-Woudenberg IA.

Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):723-34.

PMID:
19822089
38.

Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

van de Sande WW, Mathot RA, ten Kate MT, van Vianen W, Tavakol M, Rijnders BJ, Bakker-Woudenberg IA.

Antimicrob Agents Chemother. 2009 May;53(5):2005-13. doi: 10.1128/AAC.01556-08. Epub 2009 Feb 23.

39.

Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis.

van de Sande WW, van Vianen W, ten Kate MT, Vissers J, Laurijsens J, Tavakol M, Rijnders BJ, Mathot RA, Bakker-Woudenberg IA.

Antimicrob Agents Chemother. 2008 Apr;52(4):1345-50. doi: 10.1128/AAC.00536-07. Epub 2008 Jan 14.

40.

Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice.

de Steenwinkel JE, van Vianen W, Ten Kate MT, Verbrugh HA, van Agtmael MA, Schiffelers RM, Bakker-Woudenberg IA.

J Antimicrob Chemother. 2007 Nov;60(5):1064-73. Epub 2007 Sep 10.

PMID:
17846106
41.

Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection.

Goessens WH, Mouton JW, ten Kate MT, Bijl AJ, Ott A, Bakker-Woudenberg IA.

J Antimicrob Chemother. 2007 Mar;59(3):507-16. Epub 2007 Feb 8.

PMID:
17289765
42.
43.

Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis.

Berbée JF, van der Hoogt CC, Kleemann R, Schippers EF, Kitchens RL, van Dissel JT, Bakker-Woudenberg IA, Havekes LM, Rensen PC.

FASEB J. 2006 Oct;20(12):2162-4. Epub 2006 Aug 25.

PMID:
16935938
44.

Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.

Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG.

Antimicrob Agents Chemother. 2006 May;50(5):1852-4.

45.

Pathophysiology of unilateral pulmonary aspergillosis in an experimental rat model.

Becker MJ, De Marie S, Fens MH, Haitsma JJ, Verbrugh HA, Lachmann B, Bakker-Woudenberg IA.

Med Mycol. 2006 Mar;44(2):133-9.

PMID:
16519016
46.

Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.

van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker-Woudenberg IA.

J Antimicrob Chemother. 2006 Apr;57(4):732-40. Epub 2006 Feb 7.

PMID:
16464895
47.
48.

Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.

Bakker-Woudenberg IA, van Vianen W, van Soolingen D, Verbrugh HA, van Agtmael MA.

Antimicrob Agents Chemother. 2005 Jun;49(6):2387-98.

50.

Long-circulating sterically stabilized liposomes in the treatment of infections.

Bakker-Woudenberg IA, Schiffelers RM, Storm G, Becker MJ, Guo L.

Methods Enzymol. 2005;391:228-60.

PMID:
15721385

Supplemental Content

Loading ...
Support Center